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ease  in  domestic  animals  (e.g.,  pigs) 
and humans has reached an alarming 
level  (Table).  Human  infection  rates 
in  certain  areas  in  China  have  been 
high; for example, in Inner Mongolia, 
samples collected from 1,529 random-
ly selected persons during 1994–1996 
showed that 35.3% of the local popula-
tion, 57.0% of local pregnant women, 
and  100%  of  newborns  of  infected 
mothers were positive for hemotrophic 
mycoplasma  infection  (2).  Infections 
in animals in China have been recog-
nized since 1995, and the number of 
cases has been increasing rapidly. For 
example, >600,000 pigs infected with 
M. suis were reported in 2003 (Table). 
These infections have had a large eco-
nomic  impact  on  regions  where  the 
infection is endemic (8). Infections in 
other animals, including cows, sheep, 
and foxes, were also common, indicat-
ing a high prevalence of the bacteria in 
China. However, because of the lack of 
in vitro cultivation systems that assist 
in  characterizing  pathogens,  progress 
in  species  identification  and  molecu-
lar characterization of these pathogens 
has been slow. Thus far, names of he-
motrophic  mycoplasma  species  have 
been  based  on  the  hosts  from  which 
they were identified. Due to the zoonot-
ic nature of these pathogens, more in-
depth studies on these microorganisms 
are needed. 
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Sensitivity of  
Andes Hantavirus 
to Antiviral  
Effect of Human 
Saliva
To  the  Editor:  Hantaviruses 
cause 2 severe and often fatal human 
diseases, hemorrhagic fever with renal 
syndrome (HFRS) in Eurasia and han-
tavirus  cardiopulmonary  syndrome 
(HCPS) in the Americas. Rodents are 
the natural hosts for hantaviruses that 
cause HFRS and HCPS, and humans 
are usually infected by aerosolized vi-
rus-contaminated rodent excreta (1,2). 
Except  for  Andes  virus  (ANDV), 
human-to-human  transmission  of 
hantaviruses does not seem to occur. 
ANDV clearly is transmitted directly 
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Table.	Number	of	reported	hemotrophic	mycoplasma	infections,	China,	1994–2007*	
Species
Year	 Human Cow	 Swine	 Sheep Fox
1994 200 NR NR NR NR
1995 331 132 NR 231 NR
1996 1,229 259 147 NR NR
1997 2,262 69 1,282 126 NR
1998 740 64 127 115 NR
1999 3,861 1,460 397 2,493 954
2000 1,971 2,920 140 NR 371
2001 329 329 7,775 NR 16,697
2002 126 NR 17,068 NR 17,068
2003 880 84 600,033 1,877 31,208
2004 4 625 15,604 206 NR
2005 451 119 27,268 2,916 20
2006 4 75 15,916 536 465
2007 452 3 1,686 53 60
*NR,	no	record.	
1These	authors	contributed	equally	to	this	
article.LETTERS
from human to human (3), but exactly 
how this occurs or why other patho-
genic hantaviruses are not transmitted 
between humans is not known.
ANDV antigen has been detected 
in the secretory cells of the salivary 
glands  of  humans  (4).  The  risk  for 
infection  with  ANDV  is  higher  in 
people having sex or involved in deep 
kissing with an infected person than 
in other contacts (5), suggesting that 
transmission  of  ANDV  needs  close 
person-to-person  contact.  Therefore, 
one can speculate that ANDV is likely 
to be secreted into saliva and that sa-
liva  is  involved  in  human-to-human 
transmission.  Hantaviruses  can  be 
transmitted  through  saliva  between 
the natural hosts (6,7), indicating that 
hantaviruses  can  withstand  the  anti-
viral effects of saliva or can interfere 
with production of saliva and thereby 
inhibit its antiviral effect.
We  recently  showed  that  saliva 
from Puumala hantavirus (PUUV)–in-
fected humans contains viral RNA (8). 
This finding suggests that PUUV, and 
perhaps other hantaviruses, might be 
secreted into human saliva. However, 
we  found  no  evidence  of  replicat-
ing virus in the saliva samples (8,9); 
neutralizing  antibodies  or  salivary 
components may have inactivated the 
virus. We therefore analyzed the effect 
of saliva on the prototype hantavirus, 
Hantaan virus (HTNV). Our analysis 
shows that although HTNV is sensi-
tive  to  the  overall  antiviral  capacity 
of human saliva from healthy donors, 
it is insensitive to the antiviral effects 
of  certain  salivary  components,  i.e., 
histatin 5, lactoferrin, lysozyme, and 
secretory leukocyte protease inhibitor 
(9), which are known to have antiviral 
effects against other viruses.
We  tested  the  hypotheses  that 
ANDV  might  be  less  sensitive  than 
HTNV  and  PUUV  to  the  antiviral 
effect  of  human  saliva.  Saliva  from 
healthy persons with no evidence of 
seropositivity against hantavirus was 
pooled  and  preincubated  at  different 
concentrations  with  10,000  focus-
forming units of ANDV (strain Chile-
9717869), HTNV (strain 76-118), or 
PUUV (strain Kazan E6) for 1 hr (9). 
The  virus  plus  saliva  mixtures  were 
then titrated on Vero E6 cells. Virus 
without saliva was used as a control. 
The medium used for dilution of sa-
liva  and  virus  was  Hank’s  balanced 
salt solution (Invitrogen, Paisley, UK) 
supplemented with 2% fetal calf se-
rum, 2% HEPES, 100 U of penicillin/
mL, and 100 µg of streptomycin/mL. 
Because of a cytopathic effect on the 
cells, we could not test saliva concen-
trations  >50%  (9). After  incubation, 
titers in samples incubated with saliva 
were  calculated  and  compared  with 
titers  from  virus  incubated  without 
saliva.
The different hantaviruses clearly 
differed in their sensitivities to human 
saliva. At a low concentration (12.5% 
saliva), we observed a slight effect on 
HTNV, even though we saw no effect 
on ANDV and PUUV. ANDV was the 
only  virus  that  resisted  higher  con-
centrations of saliva (25% and 50%), 
and an antiviral effect was clearly ob-
served on HTNV and PUUV at these 
saliva concentrations (Figure).
Our  finding  that  ANDV  is  less 
sensitive than HTNV and PUUV to the 
antiviral effect of human saliva might 
explain why ANDV, but not HTNV or 
PUUV, is transmitted between humans. 
Saliva might be the preferred route of 
transmission for ANDV between hu-
mans, as it is for the long-tailed rice 
rat (Oligoryzomys longicaudatus), the 
natural  host  for  ANDV  (10).  How-
ever, transmission of ANDV between 
rodents, from rodents to humans, and 
between  humans  differs.  Replicating 
hantaviruses  have  not  been  isolated 
from saliva of patients with HFRS or 
HCPS. In patients who have serocon-
verted, hantavirus-specific antibodies 
are likely to be present and might ef-
ficiently neutralize the virus, including 
ANDV. If this is the case, the interval 
might be short between excretion of 
the virus into the saliva and serocon-
version, enabling the infected person 
to transmit hantavirus to other humans. 
Ferres  et al. showed  that in persons 
who  developed  HCPS  after  human-
to-human  transmission  of  ANDV, 
viremia preceded onset of disease and 
detection of ANDV-specific antibod-
ies by up to 2 weeks (5). Sampling of 
saliva  from  healthy  household  con-
tacts to ANDV-infected persons, with 
subsequent  virus  isolation  attempts, 
might show whether human saliva is 
the  mode  of ANDV  transfer  during 
human-to-human transmission.
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Figure.	 Antiviral	 effect	 of	 human	 saliva	 against	 Hantaan	 virus	 (HTNV),	 Andes	 virus	
(ANDV),	and	Puumala	hantavirus	(PUUV).	Data	represent	mean	+	SD	of	3	independent	
experiments.LETTERS
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Spread of  
Cantagalo Virus to 
Northern Brazil
To the Editor: Cantagalo virus 
(CTGV) is a strain of vaccinia virus 
(VACV;  Poxviridae)  that  was  iso-
lated  from  pustular  lesions  on  dairy 
cattle  and  dairy  workers  in  Rio  de 
Janeiro  State,  Brazil,  in  1999  (1). 
Subsequently,  similar  lesions  caused 
by poxviruses have been reported in 
cattle  and  humans  in  all  4  states  of 
the southeast region of Brazil and in 
Goiás State in central-western Brazil 
(online Technical Appendix, panel A, 
available  from  www.cdc.gov/EID/ 
content/15/7/1142-Techapp.pdf)  (2–7).   
Etiologic agents were VACV strains, 
most of which were genetically related 
to CTGV, such as Araçatuba and Pas-
satempo viruses (2,4), with the excep-
tion of Guarani P1 virus, which was 
isolated in Minas Gerais State in 2001 
and is phylogenetically close to VACV 
strain WR (5). Reisolation of Guarani 
P1  virus  has  not  been  reported. All 
VACV isolates related to CTGV share 
2 molecular signatures: an 18-nt dele-
tion in the A56R gene, which encodes 
viral hemagglutinin (1–7), and a 15-nt 
deletion in K2L gene, which encodes 
serine protease inhibitor-3 (8,9). Other 
VACV strains unrelated to CTGV were 
isolated from rodents in Brazil before 
1999, but reisolation of these viruses 
has not been described (8). Although 
CTGV-like  disease  has  not  been  re-
ported  in  the  northern,  northeastern, 
and southern regions of the country, 
rapid interstate spread of CTGV infec-
tion is of concern. We report an epi-
sode of CTGV infection in Tocantins 
State, northern Brazil (online Techni-
cal Appendix, panel A). 
In September 2008, teat and ud-
der lesions were found on 15 of 356 
febrile  (39.5°C–40°C)  cattle  on  a 
dairy farm in the municipality of Mu-
ricilândia.  Small  papules  progressed 
to vesicles and pustules (online Tech-
nical Appendix, panel B), which usu-
ally healed in 3–4 weeks. New lesions 
subsequently appeared on previously 
healthy cows on the same farm, and 
muzzle lesions developed on suckling 
calves. Dairy workers reported fever 
and lesions on their hands and neck. 
The farm was quarantined for 3 weeks 
until the condition was diagnosed. 
Four scab samples were sent for 
virus identification by PCR. Parts of 
the samples were used to infect BSC-
40  cells  and  for  DNA  isolation  by 
phenol-chloroform  extraction,  as  de-
scribed (6). After 48 hours, a strong 
cytopathic  effect  suggested  poxvirus 
infection.  The  PCR  used  unambigu-
ously  differentiates  CTGV-related 
infections  from  other  orthopoxvirus 
diseases, including cowpox virus and 
several VACV strains (6). The reverse 
primer  targets  nucleotide  sequences 
flanking the deletion signature of the 
hemagglutinin  gene  from  CTGV-
related  viruses. Therefore,  a  specific 
annealing site for the reverse primer 
is  produced  when  these  external  se-
quences are contiguous, as occurs in 
CTGV (6). 
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